Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sunitinib works in treating patients with recurrent
and/or metastatic head and neck cancer. Sunitinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.